The clinical trial investigates the efficacy of semaglutide, a GLP-1 receptor agonist, in improving psoriasis symptoms in patients with Type 2 Diabetes Mellitus (DMT2). Given the increasing prevalence of both conditions, successful outcomes could position semaglutide as a dual-action therapy, potentially expanding its market share beyond diabetes management into dermatological applications. This could enhance competitive positioning against other GLP-1 receptor agonists and psoriasis treatments. The trial's completion in June 2024 may provide timely data for strategic planning and market entry considerations, particularly in regions with high psoriasis prevalence.